Skip to main content

Table 2 Comparison of laboratory parameters and baseline characteristics among the three groups of SFTS patients

From: The associations between fasting blood glucose levels and mortality of SFTS in patients

Variables Group A (n = 19) Group B (n = 18) Group C (n = 40) p-Value
Age, years, median (IQR) 62.0 (51.0–68.0) 58.5 (53.8–70.0) 66.0 (63.0–70.0) 0.059
Sex
 Female, n (%) 8 (42.1) 8 (44.4) 26 (65.0) 0.158
 Male, n (%) 11 (57.9) 10 (55.6) 14 (35.0)  
Onset symptoms
 Fever, n (%) 19 (100) 17 (94.4) 39 (97.5) 0.568
 Cough, n (%) 6 (31.6) 8 (44.4) 18 (45.0) 0.144
 Expectoration, n (%) 3 (15.8) 5 (27.8) 16 (40.0) 0.162
 Muscular soreness, n (%) 11 (57.9) 12 (66.7) 16 (40.0) 0.131
 Fatigue, n (%) 15 (78.9) 11 (61.1) 32 (80.0) 0.278
 Diarrhoea, n (%) 7 (36.8) 10 (55.6) 20 (50.0) 0.491
 Time from onset to admission, median (IQR), d 7.0 (5.0–8.0) 5.0 (4.0–7.0) 5.0 (5.0–7.0) 0.357
 FBG (mmol/L) 4.91 (4.42–5.22) 6.16 (5.96–6.54) 10.23 (8.71–12.93) < 0.01
 Leukocytes (×109/L) 4.02 (1.63–5.07) 2.80 (1.93–3.34) 1.94 (1.30–2.93) 0.026
 Neutrophils (× 109/L) 2.06 (0.87–2.73) 1.38 (0.94–2.07) 1.12 (0.73–1.98) 0.159
 Platelet (×109/L) 54.0 (34.0–69.0) 45.0 (40.7–73.0) 40.5 (30.0–59.0) 0.108
 CRP (mg/L) 3.9 (0.8–10.43) 3.57 (0.69–6.57) 3.1 (1.15–10.17) 0.635
 Procalcitonin (mg/L) 0.11 (0.05–0.45) 0.09 (0.06–0.15) 0.20 (0.11–0.37) 0.067
 IL-1β (pg/mL) 6.85 (5.0–11.95) 9.02 (5.0–18.8) 9.74 (5.0–16.6) 0.489
 IL-2R (U/mL) 955 (748–1353) 1151 (941–1369) 1352 (1031–1678) 0.106
 IL-6 (pg/mL) 7.58 (3.2–24.0) 12.8 (6.63–59.9) 13.0 (7.14–34.3) 0.172
 IL-8 (pg/mL) 17.3 (12.8–28.3) 25.5 (17.05–50.5) 27.2 (17.7–47.9) 0.057
 IL-10 (pg/mL) 11.65 (7.2–27.3) 24.9 (11.0–56.9) 61.7 (43.2–139.0) 0.0001
 TNF-α (pg/mL) 18.2 (13.3–27.0) 16.6 (14.2–25.5) 23.2 (17.0–43.0) 0.042
 AST (U/L) 110 (84.0–147) 125.5 (98.0–204.7) 227.5 (101.7–425.5) 0.021
 ALT (U/L) 78.0 (39.0–89.0) 69.5 (44.5–98.5) 86.5 (54.7–120.5) 0.422
 CRE (μmol/L) 72.8 (53.6–86.2) 83.9 (59.5–101.8) 71.5 (60.1–91.3) 0.592
 LDH (U/L) 723 (531–1314) 798 (500–1353) 1177 (754–2322) 0.059
 CK (U/L) 239 (93–686) 362 (107–1679) 406 (158–1007) 0.427
 PT (S) 13.7 (12.7–14.5) 13.3 (12.8–13.6) 13.5 (12.7–14.2) 0.477
 APTT (S) 45.7 (39.9–58.9) 51.2 (48.7–54.1) 54.5 (47.5–65.3) 0.184
 FIB (g/L) 2.98 (2.6–3.85) 2.77 (2.42–3.25) 2.78 (2.35–3.46) 0.429
 D-Dimer (μg/ml) 1.54 (1.24–1.89) 2.47 (1.44–3.34) 3.84 (1.75–8.93) 0.003
 FDP (μg/ml) 4.92 (3.55–5.78) 6.28 (4.03–11.31) 11.79 (6.01–30.58) 0.002
 Serum amyalse (U/L) 81 (30–353) 88.5 (34–458) 109 (43–681) 0.264
 Serum lipase (U/L) 518 (44–2000) 559 (58–2000) 625 (27–2000) 0.416
 Secondary infection, n (%) 8 (42.1) 5 (27.8) 22 (55.0) 0.148
 Median length of in-hospital stay (days), median (IQR) 10.0 (9.0–12.0) 10.5 (6.5–15.0) 11.0 (8.0–16.0) 0.465
 Mortality (n, %) 5.3% 22.2% 27.5% 0.14